Comparison of subcutaneous GLP-1 receptor agonists, semaglutide and dulaglutide, on HbA1c and weight loss outcomes: A systematic review
DOI:
https://doi.org/10.22024/UniKent/03/ajpp.1365Resumen
Background: The aim of this systematic review was to ascertain whether semaglutide is more effective than dulaglutide on outcomes of glycosylated haemoglobin (HbA1c) and weight loss in adults. The objectives were to identify studies that compared the subcutaneously administered formulations of the two drugs, compare changes in outcomes stated, analyse the data and evaluate each drugs’ effectiveness and determine which drug is more effective at achieving the outcomes.
Methods: Studies were eligible for inclusion if they were published up to December 2023, written in the English language and involved adult participants only. Studies were excluded if they were of a qualitative methodology, contained paediatric samples, those that involved other subtypes of diabetes mellitus, including gestational diabetes and studies that investigated only semaglutide or dulaglutide. Two electronic databases, Medline and Embase, were searched up to 31 December 2023 for published studies with at least 3-month follow-up that compared semaglutide and dulaglutide on the outcomes of changes in HbA1c and weight. Included studies were assessed for risk of bias using the Cochrane Collaboration risk-of- bias tool v2.0 and the Risk of Bias in Non-randomised studies of Interventions tool, as appropriate. Data on the outcomes were then considered for appropriateness for statistical analyses. All included studies were deemed unsuitable for statistical analyses due to inconsistencies of implied data distributions and use of statistical methods and were therefore synthesised using descriptive statistics and a narrative analysis.
Results: A total of 3 studies (1343 participants) met the inclusion criteria, where study 1 was a non- randomised cohort study, and study 2 and 3 were randomised controlled open-label studies. Statistical analysis was unable to be conducted without reducing the validity of the analysis, due poor use of statistics overall within all the studies. As a result, a narrative analysis was conducted. Both semaglutide and dulaglutide were shown to reduce HbA1c and weight from baseline, with semaglutide showing overall greater reductions in both HbA1c and weight reduction. Overall, participants on semaglutide were more likely to experience adverse events and discontinue treatment due to this. However, dulaglutide was found to have higher rates of serious adverse events and death related to treatment than semaglutide.
Conclusions: Evaluation of the three studies showed that both GLP1-RAs are effective at reducing HbA1c and weight, with semaglutide achieving greater reductions in both outcomes overall. However, more robust and long-term studies needed on real-life populations to better determine the real-world, long-term efficacy and safety of these drugs.
In addition, it was concluded that more needs to be done to increase research proficiency in healthcare, especially in the field of statistics. Better training should be sought on the conduction of statistical analyses and reporting of research, such as the reporting of normalised data, so readers and future systematic reviews may make robust comparisons between studies.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
AJPP requests that, as the creator(s)/author(s) of the manuscript you are submitting, that you assign certain rights to the manuscript to the AJPP in exchange for undertaking to publish the article in electronic form and, in general, to pursue its dissemination throughout the world. The rights the AJPP requests are:
- The right to publish the article in electronic form or in any other form it may choose that is in keeping with its role as a scholarly journal with the goal of disseminating the work as widely as possible;
- The right to be the sole publisher of the article for a period of 12 months;
- The right to make the article available to the public within a period of not more than 24 months, as determined by relevant journal staff of the AJPP;
- The right to grant republication rights to itself or others in print, electronic, or any other form, with any revenues accrued to be shared equally between the author(s) and the journal;
- The right to administer permission to use portions of the article as requested by others, seeking recompense when the AJPP sees it as warranted;
- The right to seek or take advantage of opportunities to have the article included in a database aimed at increasing awareness of it;
- As the author(s), the AJPP wishes you to retain the right to republish the article, with acknowledgement of the AJPP as the original publisher, in whole or in part, in any other pbulication of your own, including any anthology that you might edit with up to three others;
- As the author(s), the AJPP wishes you to retain the right to place the article on your personal Web page or respository of your university or institution. The AJPP askes that you include this notice: A fully edited, peer-reviewed version of this article was first published by the Advanced Journal of Professional Practice, <Year>, <Volume>, <Issue>, <Page Numbers>.
- You retain the right to unrestricted use of your paper for yourself or for your own teaching purposes.
BY AGREEING TO THE FOREGOING, YOU CONFIRM THAT THE MANUSCRIPT YOU ARE SUBMITTING HAS NOT BEEN PUBLISHED ELSEWHERE IN WHOLE OR IN PART, AND THAT NO AGREEMENT TO PUBLISH IS OUTSTANDING.
SHOULD THE ARTICLE CONTAIN MATERIAL WHICH REQUIRES WRITTEN PERMISSION FOR INCLUSION, YOU AGREE THAT IT IS YOUR OBLIGATION IN LAW TO IDENTIFY SUCH MATERIAL TO THE EDITOR OF THE AJPP AND TO OBTAIN SUCH PERMISSION. THE AJPP WILL NOT PAY ANY PERMISSION FEES. SHOULD THE AJPP BE OF THE OPINION THAT SUCH PERMISSION IS NECESSARY, IT WILL REQUIRE YOU TO PURSUE SUCH PERMISSSION PRIOR TO PUBLICATION.
AS AUTHOR(S), YOU WARRANT THAT THE ARTICLE BEING SUBMITTED IS ORIGINAL TO YOU.
Provided the foregoing terms are satisfactory, and that you are in agreement with them, please indicate your acceptance by checking the appropriate box and proceed with your submission.
